The global pharmaceutical company Lupin is based in Mumbai, Maharashtra. The company’s main focus areas are pediatrics, anti-infectives, cardiovascular, asthma, diabetology, and anti-tuberculosis. Lupin is now trading at a PE ratio of 50 and has moved more than 12.79% in the last month and 59.79% in the last six months. We’ll examine if it makes sense to purchase, hold, or sell Lupin shares in this piece.
LUPIN Ltd. Financials
- Open – 1970 Rupees (July Month)
- High – 1974 Rupees (July Month)
- Low – 1924 Rupees (July Month)
- Day range – ₹1,924.20 – ₹1,974.00
- Year range – ₹1,043.50 – ₹1,984.00
- Market cap – 878.79B INR
- Avg Volume – 1.41M
- P/E ratio – 46.22
- Dividend yield – 0.41%
- SALES GROWTH – -4.36%
- PROFIT GROWTH – 325.34 %
LUPIN Share Price Target 2024
|
Month |
Target Price(approx.) |
| August 2024 target | ₹2010 |
| September 2024 target | ₹2123 |
| October 2024 target | ₹2224 |
| November 2024 target | ₹2295 |
| December 2024 target | ₹2526 |
LUPIN Share Price Target 2025
|
Month |
Target Price(approx.) |
| January 2025 target | ₹2883 |
| February 2025 target | ₹2941 |
| March 2025 target | ₹3000 |
| April 2025 target | ₹2900 |
| May 2025 target | ₹2803 |
| June 2025 target | ₹2710 |
| July 2025 target | ₹2818 |
| August 2025 target | ₹2931 |
| September 2025 target | ₹3048 |
| October 2025 target | ₹3109 |
| November 2025 target | ₹3171 |
| December 2025 target | ₹3234 |
LUPIN Share Price Target 2026
|
Month |
Target Price (approx.) |
| January 2026 target | ₹3299 |
| February 2026 target | ₹3365 |
| March 2026 target | ₹3432 |
| April 2026 target | ₹3318 |
| May 2026 target | ₹3208 |
| June 2026 target | ₹3101 |
| July 2026 target | ₹3225 |
| August 2026 target | ₹3354 |
| September 2026 target | ₹3488 |
| October 2026 target | ₹3558 |
| November 2026 target | ₹3629 |
| December 2026 | ₹3702 |
LUPIN Share Price Target 2027
|
Month |
Target Price (approx.) |
| January 2027 target | ₹3776 |
| February 2027 target | ₹3852 |
| March 2027 target | ₹3929 |
| April 2027 target | ₹3798 |
| May 2027 target | ₹3672 |
| June 2027 target | ₹3550 |
| July 2027 target | ₹3692 |
| August 2027 target | ₹3840 |
| September 2027 target | ₹3994 |
| October 2027 target | ₹4074 |
| November 2027 target | ₹4155 |
| December 2027 target | ₹4238 |
About Lupin Ltd
Lupin Ltd is a global pharmaceutical firm founded in 1968 and headquartered in Mumbai, India. Lupin Ltd engages in a variety of businesses, including branded and generic formulations, biotechnology, active pharmaceutical ingredients (APIs), and animal health products.
The company’s best-selling prescription and over-the-counter pharmaceuticals include antibiotics, cardiovascular meds, antidiabetics, and anti-asthmatics. Lupin Ltd also produces and promotes a number of branded medications, such as Metoject, Lupitac, and Lupizole. In addition, the company manufactures several prominent generic medications, including Amlodipine, Montelukast, and Cetirizine.
If you have invested in Lupine Share Price Target 2024, 2025, 2026, or would like to invest in it in the future, we have provided you with all the information you need to make that decision. Because we have conducted a fundamental to technical analysis in this post and provided you with information about the next activities, it may therefore prove to be very significant for you.